Current disease status-Recurrent lymphoma - Page 2 of 12 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent lymphoma Posts on Medivizor

Seeking patients with relapsed follicular lymphoma for dosing study of idelalisib

Seeking patients with relapsed follicular lymphoma for dosing study of idelalisib

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will evaluate the best dose of idelalisib (Zydelig) for patients with relapsed follicular lymphoma (FL). The primary outcomes are overall response and side effects.  The details FL is a slow-growing cancer of B-cells, a type of white blood cell. Idelalisib is a medication that inhibits certain proteins involved in...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomas

Posted by on Sep 13, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the effectiveness and safety of lisocabtagene maraleucel (Liso-cel) in treating patients with relapsed or refractory (r/r) large B-cell lymphomas (LBCL). The authors found that liso-cel achieved fast and lasting remission with fewer toxicities in such patients. Some background Patients with r/r-LBCL experience...

Read More

The effects of a second autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma after a first transplant

The effects of a second autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma after a first transplant

Posted by on Aug 9, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the outcomes of second autologous stem cell transplantation (ASCT2) in patients with relapsed/refractory Hodgkin lymphoma (r/r-HL) after a first transplantation (ASCT1). The main finding was that ASCT2 was safe and relatively effective in such patients. Some background ASCT replaces cancerous bone marrow with healthy...

Read More

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Can immunotherapy increase the effectiveness of following treatments for patients with relapsed or unresponsive non-Hodgkin lymphoma?

Posted by on Jun 21, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...

Read More

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Zanubrutinib treatment for relapsed or unresponsive small lymphocytic lymphoma

Posted by on May 31, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients.    Some background Bruton tyrosine...

Read More

How safe and effective is targeted therapy abemaciclib for patients with relapsed or refractory mantle cell lymphoma?

How safe and effective is targeted therapy abemaciclib for patients with relapsed or refractory mantle cell lymphoma?

Posted by on May 24, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the safety and effectiveness of targeted therapy abemaciclib (Verzenio) for patients with relapsed or refractory mantle cell lymphoma (MCL). The results showed that abemaciclib had promising effectiveness and was relatively safe in these patients. Some background MCL is an aggressive type of lymphoma. During...

Read More

Evaluating brentuximab vedotin plus bendamustine for patients with hard-to-treat classical Hodgkin lymphoma

Posted by on Mar 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of brentuximab vedotin (Adcetris) plus bendamustine (Treanda) for patients with hard to treat classical Hodgkin lymphoma (cHL). This study found that this regimen is an effective salvage therapy for these patients. Some background Standard first-line chemotherapy is highly effective in treating...

Read More

Evaluating the R-BAC regimen for patients with MCL that stops responding to TKI therapy

Posted by on Feb 22, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...

Read More